沈琳 Lin Shen

沈琳教授，主任医师、教授、博士生导师，现任北京大学肿瘤医院消化肿瘤内科主任、I期临床试验病区主任，北京市政协委员。历任北京大学肿瘤医院副院长、北京市肿瘤防治研究所副所长。担任中国抗癌协会肿瘤药物临床研究专业委员会首届主任委员、中国抗癌协会肿瘤精准治疗专业委员会主任委员、中国临床肿瘤学会临床研究专家委员会主任委员等多个重要学术职务。享受国务院政府特殊津贴，获全国优秀科技工作者、全国三八红旗手等荣誉称号，入选”北京学者”、北京市突出贡献专家。沈琳教授长期致力于消化道肿瘤精准治疗及抗肿瘤新药的临床与转化研究。主要贡献包括:建立消化道肿瘤临床与转化研究体系，并入选中国科协”科创中国”先导技术榜；牵头众多新药临床研究，推动抗肿瘤新药成功获批上市。在Nature、BMJ、Nature Medicine、JCO等国际权威期刊发表SCI论文近200篇，拥有国家专利10项，并主编/参编40余部胃肠肿瘤诊疗规范。科研成果屡获国家科技进步二等奖、教育部科技进步一等奖、中华医学科技奖一等奖、中国抗癌协会科技奖一等奖、华夏医学科技奖一等奖及二等奖等。

Professor Lin Shen, Chief Physician, Professor, and Doctoral Supervisor, currently serves as Director of the Department of Gastrointestinal Oncology and Director of Phase I Clinical Trial Ward at Peking University Cancer Hospital, and is a member of the Beijing Municipal Committee of the Chinese People’s Political Consultative Conference. Previously served as Vice President of Peking University Cancer Hospital and Deputy Director of Beijing Cancer Prevention and Treatment Research Institute. Holds multiple important academic positions including inaugural Chairman of the Professional Committee on Clinical Research of Cancer Drugs of the Chinese Anti-Cancer Association, Chairman of the Professional Committee on Precision Cancer Treatment of the Chinese Anti-Cancer Association, and Chairman of the Expert Committee on Clinical Research of the Chinese Society of Clinical Oncology. Enjoys special government allowances from the State Council, has been honored with titles such as National Outstanding Science and Technology Worker and National March 8th Red-Banner Pacesetter, and has been selected as a “Beijing Scholar” and Beijing Outstanding Contribution Expert. Professor Shen Lin has long been committed to clinical and translational research on precision treatment of gastrointestinal tumors and new anti-cancer drugs. Major contributions include: establishing a clinical and translational research system for gastrointestinal tumors, which was selected for the China Association for Science and Technology’s “Innovation China” pioneering technology list; leading numerous new drug clinical studies and promoting the successful approval and marketing of new anti-cancer drugs. Has published nearly 200 SCI papers in international authoritative journals such as Nature, BMJ, Nature Medicine, and JCO, holds 10 national patents, and has edited/co-edited over 40 gastrointestinal tumor diagnosis and treatment guidelines. Research achievements have repeatedly won the Second Prize of National Science and Technology Progress Award, First Prize of Ministry of Education Science and Technology Progress Award, First Prize of Chinese Medical Science and Technology Award, First Prize of Chinese Anti-Cancer Association Science and Technology Award, and First and Second Prizes of Huaxia Medical Science and Technology Award.

1. Lu Z, Wang J, Shu Y, … Shen L*. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15). BMJ. 2022; 377:e068714. IF 105.7
2. Qi C, Gong J, Li J, … Shen L*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine. 2022; 28(6):1189–1198. IF 82.9
3. Shen L#*, Kato K, Kim SB, … Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302). J Clin Oncol. 2022; 40(26):3065–3076. IF 45.3